Fight Aging! Newsletter, February 8th 2021

This study was divided in two phases: CALERIE-1 and CALERIE-2. CALERIE-1 study was performed to assess the possible effects induced by a reduction of 10-30% of caloric intake on body composition parameters and lipid profile after 6 and 12 months in a population of middle-aged non-obese subjects. CALERIE-1 results showed an improvement in lipid and glycemic profile and a reduction in body weight (BW) and fat mass. CALERIE-2 was the largest multi-center study on CRD. A total of 220 subjects were enrolled randomly with a 2:1 allocation into two subgroups: 145 in the CRD group and 75 in the ad libitum group. The CRD group followed 25% caloric restriction for two-years. After two years of diet treatment, cardiometabolic risk factors such as low-density lipoprotein cholesterol (LDL-c), total cholesterol / high-density lipoprotein cholesterol (HDL-c) ratio, SBP and DBP decreased. Moreover, serum biomarkers such as C-reactive protein, insulin sensitivity index and metabolic syndrome score were reduced. Moreover, BW was significantly lower in the CRD group when compared to the ad libitum group (average weight loss in CRD group was 7.5 kg vs average BW increase of 0.1 kg in ad libitum group). This data showed that a period of two-years of CRD was able to decrease cardiometabolic risk factors in middle-aged non-obese subjects. For this reason, it is possible to consider CRD as nutritional therapeutic approach to enhance life expectancy and reduce the onset of chronic non-c...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: 1918 Spanish Flu | Alcoholism | Alzheimer's | Amyloidosis | Biology | Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiogenic Shock | Cardiology | Cardiovascular | Chemistry | Child Development | Children | Cholesterol | Chronic Kidney Disease | Clinical Trials | Cold Sores | Conferences | Contracts | COVID-19 | Databases & Libraries | Dementia | Denmark Health | Depression | Dermatology | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diets | Disability | Eating Disorders & Weight Management | Endocrinology | Environmental Health | Epidemiology | Fatty Liver Disease (FLD) | Food and Drug Administration (FDA) | Fortamet | France Health | Funding | Gastroschisis Repair | Genetics | Germany Health | Gingivitis | Harvard | Heart | Heart Failure | Heart Transplant | Herpes | High Fat | Hormones | Hospitals | Hypertension | Inclusion-Body Myositis | Insulin | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Learning | Liver | Liver Transplant | Lung Transplant | Marketing | Metabolic Syndrome | Metformin | Mitochondria | Mitochondrial Disease | Molecular Biology | Netherlands Health | Neurology | Neuroscience | Norway Health | Nutrition | Obesity | Oral Cancer | Orthopaedics | Pandemics | Parkinson's Disease | Pathology | Pediatrics | Research | Science | Scotland Health | Smokers | Spain Health | Sports Medicine | Statistics | Stem Cell Therapy | Stem Cells | Stroke | Study | Switzerland Health | Transplants | Universities & Medical Training | Urology & Nephrology | Vitamin B3 | Vitamins | Wales Health | Weight Loss